CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells.
A Nonviral piggyBac Transposon-Mediated Method to Generate Large-Scale CAR-NK Cells from Human Peripheral Blood Primary NK Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于其固有的抗肿瘤功能和独特的“现货型”潜力,经嵌合抗原受体(CAR)基因工程改造的人自然杀伤(NK)细胞,在治疗多种血液系统恶性肿瘤和实体瘤方面前景广阔。目前,大规模生产CAR-NK细胞主要依赖mRNA转染和病毒载体转导。但mRNA CAR-NK细胞的CAR表达不稳定,而病毒载体转导通常效率较低。本章介绍一种优化方案:通过电转使用piggyBac转座子系统制备CAR-NK细胞,并进一步利用人工抗原呈递饲养细胞大规模扩增这些工程化CAR-NK细胞。该方法可高效、稳定地改造人原代NK细胞,并提供足量工程化CAR-NK细胞,以供未来潜在临床应用。
With the inherent antitumor function and unique "off-the-shelf" potential, genetically engineered human natural killer (NK) cells with chimeric antigen receptors (CARs) bear great promise for the treatment of multiple hematological malignancies and solid tumors. Current methods of producing large-scale CAR-NK cells mainly rely on mRNA transfection and viral vector transduction.
However, mRNA CAR-NK cells were not stable in CAR expression while viral vector transduction mostly ended up with low efficiency. In this chapter, we described an optimized protocol to generate CAR-NK cells by using the piggyBac transposon system via electroporation and to further expand these engineered CAR-NK cells in a large scale together with artificial antigen-presenting feeder cells.
This method can stably engineer human primary NK cells with high efficiency and supply sufficient scale of engineered CAR-NK cells for the future possible clinical applications.
MEMBER ACCOUNT
登录成功会直接打开下一页。